Quantitative
bioanalysis in plasma and tissues samples is required
to study the pharmacokinetic and pharmacodynamic properties of antisense
oligonucleotides (ASOs). To overcome intrinsic drawbacks in specificity,
sensitivity, and throughput of traditional ligand-binding assay (LBA)
and liquid chromatography–tandem mass spectrometry (LC–MS/MS)
methods, an alternative bioanalytical method was developed by combining
oligonucleotide hybridization and LC–MS/MS technologies. Target
ASOs were extracted from biological samples by hybridization with
biotinylated sense-strand oligonucleotides coupled to streptavidin
magnetic beads. Using ion-pairing chromatography and tandem mass spectrometry,
this method demonstrated high sensitivity (0.5 ng/mL using 100 μL
of plasma), high specificity, wide linear range, complete automation,
and generic applications in tests with multiple ASOs. The typical
challenge of sensitivity drop in traditional ion-pairing LC–MS/MS
was for the first time overcome by the introduction of a ternary pump
system. Due to the high specificity, quantitation in various biological
matrixes was achieved using calibration standards in plasma, largely
improving efficiency and consistency. Another major advantage was
the capability of simultaneous quantitation of ASO metabolites. The
hybridization LC–MS/MS was considered an improved alternative
for quantitation of ASOs and metabolites in plasma and tissue samples,
showing a great potential to replace traditional LBA and LC–MS/MS
methods.